The Rosen Law Firm has initiated a class action lawsuit against Mereo BioPharma Group plc, alleging that company executives made materially false and misleading statements regarding clinical trial outcomes for its investigational drug setrusumab. According to the complaint, Mereo misrepresented the confidence level and anticipated results of two Phase 3 studies—the Orbit and COSMIC trials—while withholding information that neither study achieved its primary endpoints, potentially causing investors to purchase American Depositary Shares at artificially elevated prices.
The lawsuit encompasses purchases made between June 5, 2023 and December 26, 2025, a period during which the company maintained public statements about setrusumab's efficacy for reducing fracture rates despite internal knowledge of trial failures. Investors who acquired shares during this window may be eligible for compensation through the class action mechanism. Individuals who wish to participate in the litigation or serve as lead plaintiff must act before the April 6, 2026 deadline, as failure to submit the necessary documentation could result in exclusion from potential recovery.
The case centers on allegations of securities fraud and seeks to recover losses incurred by shareholders who relied on Mereo's disclosures when making investment decisions. Affected investors are advised to consult with legal counsel to understand their rights and obligations under the class action framework.